Merck to Present New Analyses for JANUVIA® (sitagliptin) and STEGLATRO™ (ertugliflozin), and Real-World Data Studies at the 79th Scientific Sessions of the American Diabetes Association
Dateline City:
KENILWORTH, N.J.
Real-World Evidence Research to Explore Socioeconomic, Racial and Ethnic Disparities in Diabetes Treatment
KENILWORTH, N.J. – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that 25 studies, including new analyses for JANUVIA® (sitagliptin), STEGLATRO™ (ertugliflozin) and studies of real-world data, are scheduled to be presented at the 79th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, June 7 – 11, 2019. Presentations include new analyses of data with JANUVIA from the Comparative Trials with Sitagliptin (CompoSIT) program.
Language:
English
